Prognostic markers in cancer: The evolution of evidence from single studies to meta-analysis, and beyond

British Journal of Cancer

Volumn 100, Issue 8, 2009, Pages 1219-1229

  Riley, R D ^a   Sauerbrei, W ^b   Altman, D G ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Biomarker; Evidence synthesis; Guidelines; Primary studies; Prognosis; Prognostic tumour marker

Indexed keywords

PROTEIN P53;

BLADDER CANCER; CLINICAL RESEARCH; EVOLUTION; HEAD AND NECK CANCER; HUMAN; META ANALYSIS; METHODOLOGY; NEUROBLASTOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVIEW;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; GUIDELINES AS TOPIC; HUMANS; META-ANALYSIS AS TOPIC; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; PROGNOSIS; RECURRENCE; REPRODUCIBILITY OF RESULTS; RESEARCH; RISK FACTORS;

EID: 64949190936     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604999     Document Type: Review

References (80)

1. Altman DG (2001) Systematic reviews of evaluations of prognostic variables. BMJ 323: 224-228
2. Altman DG, De Stavola BL, Love SB, Stepniewska KA (1995) Review of survival analyses published in cancer journals. Br J Cancer 72: 511-518
3. Altman DG, Lausen B, Sauerbrei W, Schumacher M (1994) Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829-835
4. Altman DG, Lyman GH (1998) Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 52: 289-303
5. Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19: 453-473
6. Altman DG, Trivella M, Pezzella F, Harris AL, Pastorino U (2006) Systematic review of multiple studies of prognosis: the feasibility of obtaining individual patient data. I. In Advances in Statistical Methods for the Health Sciences, Auget J-L, Balakrishnan N, Mesbah M, Molenberghs G (eds), pp 3-18. Birkhäuser: Boston
7. Bennett DA (2003) Review of analytical methods for prospective cohort studies using time to event data: single studies and implications for meta-analysis. Stat Methods Med Res 12: 297-319
8. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C (1999) Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 28: 1-9
9. Boffetta P, Soutar A, Cherrie JW, Granath F, Andersen A, Anttila A, Blettner M, Gaborieau V, Klug SJ, Langard S, Luce D, Merletti F, Miller B, Mirabelli D, Pukkala E, Adami HO, Weiderpass E (2004) Mortality among workers employed in the titanium dioxide production industry in Europe. Cancer Causes Control 15: 697-706
10. Boracchi P, Biganzoli E (2003) Markers of prognosis and response to treatment: ready for clinical use in oncology? A biostatistician's viewpoint. Int J Biol Markers 18: 65-69
11. Brundage MD, Davies D, Mackillop WJ (2002) Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122: 1037-1057
12. Burke HB, Henson DE (1998) Specimen banks for cancer prognostic factor research. Arch Pathol Lab Med 122: 871-874
13. Burton A, Altman DG (2004) Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Br J Cancer 91: 4-8
14. Cardis E, Vrijheid M, Blettner M, Gilbert E, Hakama M, Hill C, Howe G, Kaldor J, Muirhead CR, Schubauer-Berigan M, Yoshimura T, Bermann F, Cowper G, Fix J, Hacker C, Heinmiller B, Marshall M, Thierry-Chef I, Utterback D, Ahn YO, Amoros E, Ashmore P, Auvinen A, Bae JM, Solano JB, Biau A, Combalot E, Deboodt P, Diez Sacristan A, Eklof M, Engels H, Engholm G, Gulis G, Habib R, Holan K, Hyvonen H, Kerekes A, Kurtinaitis J, Malker H, Martuzzi M, Mastauskas A, Monnet A, Moser M, Pearce MS, Richardson DB, Rodriguez-Artalejo F, Rogel A, Tardy H, Telle-Lamberton M, Turai I, Usel M, Veress K (2005) Risk of cancer after low doses of ionising radiation: retrospective cohort study in 15 countries. BMJ 331: 77
15. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, Schroeder TV, Sox HC, Van Der Weyden MB (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet 364: 911-912
16. Dupuy A, Simon RM (2007) Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99: 147-157
17. Filipits M, Haddad V, Schmid K, Huynh A, Dunant A, Andre F, Brambilla E, Stahel R, Pignon JP, Soria JC, Popper HH, Le Chevalier T, Pirker R (2007a) Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 13: 3892-3898
18. Filipits M, Pirker R, Dunant A, Lantuejoul S, Schmid K, Huynh A, Haddad V, Andre F, Stahel R, Pignon JP, Soria JC, Popper HH, Le Chevalier T, Brambilla E (2007b) Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 25: 2735-2740
19. Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22: 207-219
20. Goebell PJ, Groshen S, Schmitz-Drager BJ, Sylvester R, Kogevinas M, Malats N, Sauter G, Barton Grossman H, Waldman F, Cote RJ (2004) The International Bladder Cancer Bank: proposal for a new study concept. Urol Oncol 22: 277-284
21. Harrell FE (2001) Regression Modeling Strategies, with Applications to Linear Models, Logistic Regression, and Survival Analysis. Springer: New York
22. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast Jr RC (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312
23. Hayden JA, Cote P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144: 427-437
24. Hayden JA, Côté P, Steenstra IA, Bombardier C, QUIPS-LBP Working Group (2008) Identifying phases of investigation helps planning, appraising, and applying the results of explanatory prognosis studies. J Clin Epidemiol 61: 552-560
25. Hayes DF, Stearns V, Rae J, Flockhart D (2008) A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? J Natl Cancer Inst 100: 610-613
26. Hemingway H (2006) Prognosis research: why is Dr. Lydgate still waiting? J Clin Epidemiol 59: 1229-1238
27. Hemingway H (2007) Improving prognosis research: standards primary, secondary, and tertiary. J Clin Epidemiol 60: 865-866
28. Henderson R, Keiding N (2005) Individual survival time prediction using statistical models. J Med Ethics 31: 703-706
29. Hinestrosa MC, Dickersin K, Klein P, Mayer M, Noss K, Slamon D, Sledge G, Visco FM (2007) Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat Rev Cancer 7: 309-315
30. Holländer N, Sauerbrei W (2006) On statistical approaches for the multivariable analysis of prognostic factor studies. In Advances in Statistical Methods for the Health Sciences. Auget J-L, Balakrishnan N, Mesbah M, Molenberghs G (eds), pp 19-38. Birkhäuser: Boston
31. Horton R, Smith R (1999) Time to register randomised trials. The case is now unanswerable. BMJ 319: 865-866
32. Ioannidis JP, Rosenberg PS, Goedert JJ, O'Brien TR (2002) Commentary: meta-analysis of individual participants' data in genetic epidemiology. Am J Epidemiol 156: 204-210
33. Kattan MW (2003) Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 95: 634-635 Katz EM, Kattan MW (2005) How to judge a tumor marker. Nat Clin Pract Oncol 2: 482-483
34. Kyzas PA, Denaxa-Kyza D, Ioannidis JP (2007a) Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 43: 2559-2579
35. Kyzas PA, Denaxa-Kyza D, Ioannidis JP (2007b) Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst 99: 236-243
36. Kyzas PA, Loizou KT, Ioannidis JP (2005) Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 97: 1043-1055 Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Janicke F, Schmitt M, Foekens JA (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94: 116-128
37. Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C, Meert AP, Steels E, Vallot F, Verdebout JM, Lafitte JJ, Sculier JP (2003) Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 89: 55-64
38. McShane LM, Altman DG, Sauerbrei W (2005a) Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Inst 97: 1023-1025 McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005b) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391
39. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991
40. Parker CC, Gospodarowicz M, Warde P (2001) Does age influence the behaviour of localized prostate cancer? BJU Int 87: 629-637
41. Pencina MJ, D'Agostino SRB, D'Agostino JRB, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27: 157-172
42. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93: 1054-1061
43. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P (2004) Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159: 882-890
44. Piedbois P, Buyse M (2004) Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol 22: 3839-3841
45. Ransohoff R (2007) How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol 60: 1205-1219
46. Ravid R (2008) Standard Operating Procedures, ethical and legal regulations in BTB (Brain/Tissue/Bio) banking: what is still missing? Cell Tissue Bank 9: 121-137
47. Rifai N, Altman DG, Bossuyt PM (2008) Reporting bias in diagnostic and prognostic studies: time for action. Clin Chem 54: 1101-1103
48. Riley RD, Abrams KR, Lambert PC, Sutton AJ, Altman DG (2006a) Where next for evidence synthesis of prognostic marker studies? Improving the quality and reporting of primary studies to facilitate clinically relevant evidence-based results. In Advances in Statistical Methods for the Health Sciences. Auget J-L, Balakrishnan N, Mesbah M, Molenberghs G (eds), pp 39-58. Birkhäuser: Boston
49. Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, Burchill SA (2003) Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer 88: 1191-1198
50. Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, Young B, Wailoo AJ, Burchill SA (2004a) A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 10: 4-12
51. Riley RD, Lambert PC, Staessen JA, Wang J, Gueyffier F, Thijs L, Boutitie F (2008) Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Stat Med 27: 1870-1893
52. Riley RD, Look MP, Simmonds MC (2007a) Combining individual patient data and aggregate data in evidence synthesis: a systematic review identified current practice and possible methods. J Clin Epidemiol 60: 431-439
53. Riley RD, Ridley G, Williams K, Altman DG, Hayden J, de Vet HC (2007b) Prognosis research: toward evidence-based results and a Cochrane methods group. J Clin Epidemiol 60: 863-865
54. Riley RD, Sutton AJ, Abrams KR, Lambert PC (2004b) Sensitivity analyses allowed more appropriate and reliable meta-analysis conclusions for multiple outcomes when missing data was present. J Clin Epidemiol 57: 911-924
55. Rothstein HR, Sutton AJ, Borenstein M (eds) (2005) Publication Bias in Meta-Analysis. Wiley: Chichester
56. Royston P, Altman DG, Sauerbrei W (2006) Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 25: 127-141
57. Royston P, Sauerbrei W (2008) Multivariable Model-Building - A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Modelling Continuous Variables. Wiley: New York
58. Sargent DJ, Conley BA, Allegra C, Collette L (2005) Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23: 2020-2027
59. Sauerbrei W (1999) The use of resampling methods to simplify regression models in medical statistics. Appl Stat 48: 313-329
60. Sauerbrei W (2005) Prognostic factors - confusion caused by bad quality of design, analysis and reporting of many studies. In Current Research in Head and Neck Cancer: Advances in Oto-Rhino-Laryngology. Bier H (ed), Vol. 62, pp 184-200. Karger: Basel
61. Sauerbrei W, Holländer N, Riley RD, Altman DG (2006) Evidence-based assessment and application of prognostic markers: the long way from single studies to meta-analysis. Commun Stat 35: 1333-1342
62. Sauerbrei W, Hübner K, Schmoor C, Schumacher M (1997) Validation of existing and development of new prognostic classification schemes in node negative breast cancer. German Breast Cancer Study Group. Breast Cancer Res Treat 42: 149-163
63. Sauerbrei W, Royston P, Binder H (2007) Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 26: 5512-5528
64. Schilsky RL, Dressler LM, Bucci D, Monovich L, Jewell S, Suster S, Caligiuri MA, Kantoff PW, Compton C (2002) Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories. Clin Cancer Res 8: 943-948
65. Schmitz-Dräger BJ, Goebell PJ, Ebert T, Fradet Y (2000) p53 immuno- histochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 38: 691-699
66. Schumacher M, Holländer N, Schwarzer G, Sauerbrei W (2006) Prognostic factor studies. In Handbook of Statistics in Clinical Oncology. Crowley J, Ankerst DP (eds), 2nd edn, pp 289-333. Chapman & Hall/CRC Press: Boca Raton, FL
67. Schwarzer G, Vach W, Schumacher M (2000) On the misuse of artificial neural networks for prognostic and diagnostic classification in oncology. Stat Med 19: 541-561
68. Simes RJ (1986) Publication bias: the case for an international registry of clinical trials. J Clin Oncol 4: 1529-1541
69. Simon R (2001) Evaluating prognostic factor studies. In Prognostic Factors in Cancer. Gospodarowicz MK (ed), pp 49-56. New York: Wiley-Liss
70. Simon R, Altman DG (1994) Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69: 979-985
71. Sterne JA, Egger M, Smith GD (2001) Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 323: 101-105
72. Stewart LA, Tierney JF (2002) To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 25: 76-97
73. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F (2000) Methods for Meta-Analysis in Medical Research. Wiley: London
74. Tinker AV, Boussioutas A, Bowtell DD (2006) The challenges of gene expression microarrays for the study of human cancer. Cancer Cell 9: 333-339
75. Tudur-Smith C, Williamson PR, Marson AG (2005) Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Stat Med 24: 1307-1319
76. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358: 252-260
77. Van Meerbeeck JP (1994) Prognostic factors in malignant mesothelioma: where do we go from here? Eur Respir J 7: 1029-1031
78. Vickers AJ, Elkin EB (2006) Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 26: 565-574
79. Windeler J (2000) Prognosis - what does the clinician associate with this notion? Stat Med 19: 425-430
80. Wyatt J, Altman DG (1995) Commentary: Prognostic models: clinically useful or quickly forgotten? BMJ 311: 1539-1541